Biochem Biophys Res Commun 1989, 161:851–8.PubMedCrossRef 3. Connolly DT, Olander JV, Heuvelman D, et al.: Human vascular permeability factor. Isolation from U937 cells. J Biol Chem 1989, 264:20017–24.PubMed 4. Ferrara N: VEGF

and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002, 2:795–803.PubMedCrossRef 5. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353–64.PubMedCrossRef 6. Ferrara N, Hillan KJ, Gerber HP, Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004, 3:391–400.PubMedCrossRef 7. Gorski DH, Beckett MA, Jaskowiak NT, et al.: Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999, 59:3374–8.PubMed 8. Mauceri HJ, Hanna NN, Beckett MA, et Ruboxistaurin al.: GW786034 mw Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998, 394:287–91.PubMedCrossRef 9. Hanna NN, Seetharam S, Mauceri HJ, et al.: Antitumor interaction of short-course endostatin and ionizing radiation. Cancer J 2000, 6:287–93.PubMed 10. Li J, Huang S, Armstrong EA, Fowler JF, Harari PM: Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade. Int J Radiat Oncol Biol Phys 2005, 62:1477–85.PubMedCrossRef 11. Hoang T, Huang S, Armstrong E, Harari PM: Augmentation of radiation

response with the VEGFR-tyrosine kinase inhibitor ZD6474. Pro Am Assoc Cancer Res Mirabegron 2004, 45:955. 12. Griffin RJ, Williams BW, Wild R, Cherrington JM, Park H, Song CW: Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res 2002, 62:1702–6.PubMed 13. Zips D, Hessel F, Krause M, et al.: Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human

squamous cell carcinomas in nude mice. Int J Radiat Oncol Biol Phys 2005, 61:908–14.PubMedCrossRef 14. Siemann DW, Rojiani AM: Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2002, 53:164–71.PubMedCrossRef 15. Hoang T, Huang S, Armstrong E, Eickhoff JC, Harari PM: Augmentation of radiation response with the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2006, 64:1458–65.PubMedCrossRef 16. Li L, Rojiani A, Siemann DW: Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int J Radiat Oncol Biol Phys 1998, 42:899–903.PubMedCrossRef 17. Folkman J: Tumor angiogenesis and tissue factor. Nat Med 1996, 2:167–8.PubMedCrossRef 18. Wachsberger PR, Burd R, Marero N, et al.: Effect of the tumor vascular-damaging agent, Dehydrogenase inhibitor ZD6126, on the radioresponse of U87 glioblastoma.